Day One Biopharmaceuticals Inc. (DAWN) is a clinical-stage biopharmaceutical company focused on discovering and commercializing tailored therapeutics for patients of all ages suffering from life-threatening illnesses. The company's lead product candidate Tovorafenib (DAY101), is an investigational oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor.
The stock recently gained traction following an insider trading activity worth more than $40 million on June 17. Shares of this $1.3-billion biopharmaceutical business have risen 18.9% since then. On June 17, Non-Executive Director Michael Gladstone and Atlas Venture Opportunity Fund II, L.P. each purchased 766,667 shares of the company's stock at an average price of $15.00 per share.
